Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.
We describe a male patient who developed systemic sclerosis following orchiectomy, radiotherapy and anti-androgenic treatment for prostatic adenocarcinoma. This case appears interesting as it further supports the possibility of a relationship between neoplasia and systemic sclerosis. The concurrence of scleroderma and iatrogenic hypoandrogenism suggests that hormonal influences may also play a role in the pathogenesis of this connective tissue disorder.
Giordano
N
N
Institute of Rheumatology, University of Siena, Italy.
Magaro
L
L
Fattorini
L
L
Marcucci
P
P
Battisti
E
E
Fioravanti
A
A
Marcolongo
R
R
D000230:Adenocarcinoma / Q000188:drug therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy
D000726:Androgen Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D017373:Cyproterone Acetate; D008775:Methylprednisolone